Rizatriptan Benzoate Tablet
Product Images NDC 29300-316

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 29300-316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 01

Chemical structure of Rizatriptan Benzoate showing the arrangement of nitrogen, carbon, hydrogen, and oxygen atoms in the molecule.*

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 02

A line graph showing the estimated probability of response over time in hours post-dose for Rizatriptan Benzoate Tablets USP 5 mg and 10 mg compared to placebo. The 10 mg tablets show the highest response probability, followed by 5 mg and then placebo, with all measurements increasing from 0 to 2 hours post-dose.*

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 03

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose. It compares placebo with Rizatriptan Benzoate tablets at 5 mg and 10 mg doses, illustrating their effects over time.*

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 04

A line graph showing the estimated probability of response over time up to 2 hours post-dose for Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The graph illustrates increased response probabilities with both doses over time, with the 10 mg dose showing the highest response.*

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 05

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for Placebo, Rizatriptan Benzoate Orally Disintegrating Tablets USP 5 mg, and 10 mg. The y-axis represents probability (0%-100%) and the x-axis shows time in hours (0-24). The graph compares the response rates of the three groups over time.*

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 06

A line graph comparing the percent response (with 95% confidence intervals) over time (hours post stage 2 dose) between Rizatriptan Benzoate orally disintegrating tablets, USP, and placebo. The graph shows data points at 0.5, 1, 1.5, and 2 hours, with the Rizatriptan line consistently higher than the placebo line.*

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 07

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 08

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 09

Label for Rizatriptan Benzoate Tablets, USP, 5 mg oral tablets by Unichem Pharmaceuticals (USA), Inc. The label indicates an 18-tablet package (6 blister strips of 3 tablets each), specifying prescription-only status and includes storage instructions, manufacturer details, and a barcode. The dosage strength is prominently displayed as 5 mg.*

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 10

Packaging label for Rizatriptan Benzoate Tablets, USP, 10 mg strength. The label indicates the tablet dosage form, prescription status (Rx only), and packaging size of 18 tablets (6 blister strips of 3 tablets each). It shows the labeler as Unichem Pharmaceuticals (USA), Inc. The label includes storage instructions and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.